Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23

Lei Lei Wu

News Reporter

CHICAGO — Novartis’ CDK4/6 inhibitor Kisqali helped early breast cancer patients stay cancer-free for longer after surgery, according to interim study results presented at ASCO.

In a Phase III study, Kisqali was added on top of endocrine therapy — the current standard treatment for early breast cancer patients. Kisqali reduced the risk of disease relapse by 25% compared with endocrine therapy alone in patients with Stage II or III HR-positive, HER2-negative breast cancer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Data Quality 2.0: The Future of Real-World Evidence

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

News Reporter

Unlock this article instantly by becoming a free subscriber.

Alexandria Real Estate Equities

Cambridge, MA, USA

Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23